Specialty: Musculoskeletal disorders, Primary sub-specialty: Metabolic Bone Disease Musculoskeletal Diseases Metabolic bone disease
Conditions
Interventions
Participants are selected from an on-going longitudinal cohort study on the basis of having hip abductor weakness (determined from thresholds defined a prior from age and gender normative data) at cli
Sponsors
University of Leeds
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18-40 years 2. Reported insidious (non-traumatic) onset of anterior or retropatellar knee pain 3. Pain on two or more of the following activities: prolonged sitting, kneeling, squatting, running, patella palpation, hopping, stair walking, stepping down or isometric quadriceps contraction 4. Peak hip abduction torque values: Females [18-29 years] = 94.1nm; Females [30-39 years] = 75.8nm; Males [18-29 years] = 144.1nm; Males [30-39 years] = 139nm
Exclusion criteria
Exclusion criteria: 1. Pain referred from hip or lumbar spine 2. History of previous knee surgery 3. Presence of inflammatory arthritis 4. Other diagnosed knee conditions such as, but not restricted to, meniscal pathologies, quadriceps tendon injuries, patella tendinopathy, tibial tubercle apophysitis; bursitis. 5. Contraindications to MRI which includes: a cardiac pacemaker implanted; pacing wires left in situ after the removal of a cardiac pacemaker; cerebral aneurysm clip in situ; previous intraocular injury involving metal that has not been investigated by an x-ray previously; implantation of an electromechanical device; pregnancy; implantation of a surgical device which is not documented as safe in a 3 Tesla MR scanner
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The conversion to consent (%) is the percentage of those people who are eligible who agree to consent to the trial up to the end of recruitment 2. Eligibility rate (%) is measured as the percentage of people with PFP who are eligible for the study ( e.g.hip weakness) up to the end of recruitment 3. Adherence rate to treatment (%) is measured as the percentage of treatment session completed up to the end of the treatment period (6 weeks) 4. Adherence rate to appointments (%) is measured as the percentage of appointments attended up to the end of the treatment period (6 weeks) 5. Attrition rate (%) is measured as the percentage of participants who remain in the study until the end of follow up at 8 weeks. 6. Missing data (%) is measured as percentage of data missed in the outcome measure at 8 weeks follow up 7. Treatment efficacy is measured using a numerical rating scale, the Anterior Knee Pain Scale (AKPS) and the global rating of change scale (GROC) at 8 weeks follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Peak hip internal rotation angle (peak IR) of the thigh with respect to the pelvis is measured using VICON motion capture stystme at baseline and 8 weeks follow up 2. Peak hip adduction angle (peak ADD) of the thigh with respect to the pelvis is measured using VICON motion capture system at baseline and 8 weeks follow up 3. Total coronal hip range of movement (coronal ROM) is measured using VICON motion capture system at baseline and 8 weeks follow up 4. Total transverse hip (ROM) (transverse ROM) is measured using VICON motion capture system at baseline and 8 weeks follow up 5. Peak isokinetic hip abduction strength is measured using Biodex isokinetic dynamometer at baseline and 8 weeks follow up 6. Peak isokinetic knee extension strength is measured using Biodex isokinetic dynamometer at baseline and 8 weeks follow up | — |
Countries
United Kingdom
Contacts
Public ContactBenjamin Drew
Outcome results
None listed